Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesivir Filing
Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic.
You may also be interested in...
Keeping Track: Veklury NDA Arrives At US FDA; Olinvyk Sees Approval; MAb Filings By Regneron, Y-mAbs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
Coronavirus Update: Two UK-Backed Vaccines Progress, Cross-Industry Database Launched, Roche's Schwan On COVID-19 Impact
Plus: Korea's Dong Wha readies potent antiviral for trials, and Pharming's candidate shows promise in compassionate use.